If you are living with type 2 diabetes, it’s time to talk about your increased risk of cardiovascular events.
Fortunately, the SURPASS-CVOT clinical research study is currently underway in your area. We are looking for volunteers to join SURPASS-CVOT, a clinical research trial that will test how effective an investigational study drug is when compared to dulaglutide (an approved diabetes medication) on major adverse cardiovascular events in people with type 2 diabetes mellitus (T2DM), and a history of cardiovascular disease (CVD).
Any trial-related investigational medications, laboratory tests and assessments that are over and above normal medical care will be provided at no cost to you. Reimbursement may also be available for trial-related expenses (such as travel).
If you would like to know more, please contact us. We will be happy to answer any questions that you may have. We can also schedule an appointment so that you can learn about the study in detail and allow us to check whether you and the study are a good match.
Type of participant we are looking for:
- Diagnosed with type 2 diabetes
- Be at least 40 years of age
- Have established cardiovascular disease (e.g. History of heart attack, stroke, vascular stents, bypass, peripheral artery disease)
Clinicaltrials.gov number
NCT04255433
Who to contact:
Karen Atkinson, Ellen Demmerle
Phone number: 206-768-5338
BRIDge is a research study to facilitate the understanding of diabetes and immune-mediated diseases. The study consists of a confidential registry where we store your contact, research, and health information, and a sample repository where we keep blood samples for current and future use in our research. The samples will be used for many different studies.
An important part of this study is the sharing of information between researchers of different immune-mediated diseases. The samples and information obtained in this study are part of Benaroya Research Institute’s Immune-Mediated Diseases Registry and Repository.
We may contact you to see if you will come in for additional study visits or to update your health and contact information. We will always tell you what we need and let you decide if you are able to help us at that time. We may also contact you to let you know that you may be eligible for other studies.
Type of participant we are looking for:
- Diagnosed with type 1 diabetes
- Relatives of people with type 1 diabetes
- Live in Seattle area
Clinicaltrials.gov number
None
Who to contact:
Outreach Team at Benaroya Research Institute
Phone number: 1-800-888-4187
Email address: diabetes@BenaroyaResearch.org
Website for more details about the study:
BRIDGE Study of Type 1 Diabetes | Benaroya Research Institute
This study is testing an investigational drug called frexalimab in adolescents and adults age 12-35 years old with newly diagnosed type 1 diabetes who are on insulin therapy (adults age 18-35 will be enrolled first, followed by 12 to 21-year-olds later in the study).
You will be put into a group by chance (randomized) to receive either the study drug, frexalimab or placebo. The placebo looks just like frexalimab but does not contain any real medicine. It is used to better see if the effect of the study drug (frexalimab) in comparison to no medicine. Your chances of receiving frexalimab is 2 in 3.
You can help researchers understand:
- If frexalimab can preserve the body’s own insulin production.
- If frexalimab can help the body control blood glucose levels.
- If frexalimab can decrease the dose of insulin.
How safe frexalimab is.
Eligibility Criteria
To be considered for this study you must be:
- Age 12-35 (adults age 18-35 will be enrolled first, followed by 12 to 21-year-olds later in the study)
- Recently diagnosed with type 1 diabetes and taking insulin replacement therapy for 90 days or less.
What will study participants be asked to do?
You will be in the study for about 135 weeks (2.5 years). You will visit the study site about 14 times for tests and health checks. Your study team will also call you between visits to see how you’re doing. Your health will be monitored for any side effects that may happen.
Email: diabetes@benaroyaresearch.org
Phone: 800-888-4187
The SAFEGUARD study will evaluate the safety and efficacy of an investigational medicine called SAB-142 in delaying disease progression in people newly diagnosed with T1D.
Eligibility Criteria
To be considered for this study you must be:
- Age 15 to 40 years old with a T1D diagnosis within the past three months.
Email: diabetes@benaroyaresearch.org
Phone: 800-888-4187
The BETA PRESERVE study will look at how an investigational study drug, called teplizumab, might possibly help protect insulin-producing cells by affecting the immune cells that attack them.
Eligibility Criteria
To be considered for this study you must be:
- Age 1 to 25 years old with a T1D diagnosis within the past month.
Email: diabetes@benaroyaresearch.org
Phone: 800-888-4187
The BETA PRESERVE study will look at how an investigational study drug, called teplizumab, might possibly help protect insulin-producing cells by affecting the immune cells that attack them.
Eligibility Criteria
To be considered for this study you must be:
- Age 1 to 25 years old with a T1D diagnosis within the past month.
Email: diabetes@benaroyaresearch.org
Phone: 800-888-4187
The Benaroya Research Institute Autoimmune Registry (BRIAR) is a voluntary registry for individuals interested in participating in autoimmune disease research. Whether you live with an autoimmune condition, have a family member who does, or would like to be a healthy control volunteer, joining BRIAR helps advance scientific understanding and supports the development of future treatments.
By enrolling, you will provide basic health information that helps us match you to current and future studies, and you will receive periodic research updates from Benaroya Research Institute (BRI). All the information you provide will be kept confidential and participation in future studies is always voluntary.
Eligibility Criteria
You are eligible to join BRIAR if you have any of the following:
- a personal history of one or more autoimmune/immune-mediated condition(s)
- a healthy immune system, without any autoimmune/immune-mediated conditions
- a family history of one or more autoimmune/immune-mediated condition(s)
Parents or legal guardians may register on behalf of a child under age 18.
Email: diabetes@benaroyaresearch.org
Phone: 800-888-4187
TrialNet is an international network dedicated to the study, prevention and early treatment of type 1 diabetes. TrialNet screens relatives of people with type 1 diabetes for their risk of developing the disease and can identify the early stages of T1D years before symptoms appear. The study also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it.
With a simple blood test TrialNet looks for diabetes-related autoantibodies. If autoantibodies are confirmed to be present, participants will be invited to join the monitoring part of the study and they may be eligible to participate in a prevention trial.
Family members can order test kits to be mailed to them, free of charge, to collect a screening sample at home. To learn more or sign up, visit https://www.TrialNet.org
Type of participant we are looking for:
- Individuals 2 through 45 years old who have an immediate family member with type 1 diabetes (such as a child, parent, or sibling)
- Individuals 2 through 20 years old who have an extended family member with type 1 diabetes (such as a cousin, niece, nephew, aunt, uncle, grandparent, or half-sibling)
Clinicaltrials.gov number
NCT00097292
Who to contact:
Outreach Team at Benaroya Research Institute
Phone number: 1-800-888-4187
Email address: diabetes@BenaroyaResearch.org
Website for more details about the study:
https://www.TrialNet.org
RADIANT - Rare and Atypical Diabetes Network
The Rare and Atypical DIAbetes NeTwork (RADIANT) is dedicated to characterizing (discovering and defining) rare and atypical forms of diabetes.
RADIANT is a network of universities, hospitals and clinics across the United States dedicated to better understanding atypical diabetes. Our team of academic institutions and scientists collaborates with physicians and healthcare groups to identify those with atypical diabetes and learn more about their health.
RADIANT is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Type of participant we are looking for:
- Ages 0-80 with an atypical form of diabetes
Website for more details about the study:
https://www.atypicaldiabetesnetwork.org/
DERMIS
DERMIS is an investigational study looking to answer the questions of why pump wearers’ skin changes after a number of years.
Type of participant we are looking for:
- Type 1 adults over the age of 30, who are pump wearers either >20 years or <10 years.
Who to contact:
Dori Khakpour
Email address: dorik@uw.edu
GLIDING
GLIDING: A randomized comparison of transitioning from insulin GLargine to Insulin Degludec usING a bridging dose of glargine versus direct conversion, in patients with type 1 diabetes mellitus, is a small pilot study looking at two regimens (or treatment schedules) for people who switch from taking insulin glargine and insulin degludec.
The main purpose of this study is to see if the participants switching with a bridging dose have less low blood sugars and better blood sugar control vs those who switch with no bridging dose. The results of this research may help design other or larger studies to look at better ways of switching insulins.
Type of participant we are looking for:
- Patient who are type 1 and whose doctor wishes to change their insulin from Glargine to Degludec.
Who to contact:
Thanmai Kaleru
Email address: tkaleru@uw.edu